Who owns Parabilis Medicines, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PBLS from SEC Form 13F filings across 127 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 127 institutions disclosed 110.1M shares of Parabilis Medicines, Inc. worth $3.54B — about 89.1% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
127
13F holders
$3.54B
value, 2026 filers
89.1%
of shares outstanding (110.1M sh)
59
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of PBLS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 29.2M | $942.2M | 9.5% | 23.6% | +0.8% |
| 2 | FMR LLC | 10.9M | $336.6M | 0.0% | 8.8% | +5.6% |
| 3 | ARCH Venture Management, LLC | 6.4M | $207.1M | 12.8% | 5.2% | 0.0% |
| 4 | venBio Partners LLC | 5.3M | $170.1M | 34.3% | 4.3% | 0.0% |
| 5 | Alphabet Inc. | 4.9M | $158.9M | 0.2% | 4% | 0.0% |
| 6 | Nextech Invest Ltd. | 4.7M | $150.6M | 6.7% | 3.8% | 0.0% |
| 7 | Cormorant Asset Management, LP | 4.6M | $149.0M | 10.0% | 3.7% | 0.0% |
| 8 | REGENERON PHARMACEUTICALS, INC. | 4.2M | $134.5M | 74.9% | 3.4% | 0.0% |
| 9 | Janus Henderson Group Ltd.NEW | 3.3M | $105.8M | 0.0% | 2.7% | new |
| 10 | Siren, L.L.C. | 3.0M | $96.6M | 2.3% | 2.4% | 0.0% |
| 11 | BlackRock, Inc.NEW | 2.8M | $90.1M | 0.0% | 2.3% | new |
| 12 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 2.4M | $76.5M | 0.3% | 1.9% | 0.0% |
| 13 | Frazier Life Sciences Management, L.P. | 2.3M | $75.3M | 1.9% | 1.9% | +21.3% |
| 14 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.9M | $60.7M | 0.9% | 1.5% | 0.0% |
| 15 | Soleus Capital Management, L.P. | 1.7M | $54.4M | 1.9% | 1.4% | +15.0% |
| 16 | General Catalyst Group Management, LLC | 1.6M | $51.7M | 10.8% | 1.3% | 0.0% |
| 17 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6M | $51.1M | 0.0% | 1.3% | +21.5% |
| 18 | VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $50.3M | 0.0% | 1.3% | +34.5% |
| 19 | GENERAL ATLANTIC, L.P. | 1.5M | $49.7M | 2.0% | 1.2% | 0.0% |
| 20 | JPMORGAN CHASE & CO | 1.1M | $33.9M | 0.0% | 0.9% | +1.9% |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 1.0M | $32.5M | 0.0% | 0.8% | +911.4% |
| 22 | Foresite Capital Management VI LLC | 999,044 | $32.3M | 5.7% | 0.8% | 0.0% |
| 23 | Catalio Capital Management, LP | 824,043 | $26.6M | 4.9% | 0.7% | 0.0% |
| 24 | PRICE T ROWE ASSOCIATES INC /MD/ | 766,727 | $24.8M | 0.0% | 0.6% | +2.0% |
| 25 | ALLIANCEBERNSTEIN L.P. | 765,186 | $24.7M | 0.0% | 0.6% | -5.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.